Foci Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 39.7385 million yuan, up 32.00% from the same period last year. Total operating revenue was 440 million yuan, up 2.55% year-on-year. Net cash inflow from operating activities was 160 million yuan, up 796.82% year-on-year, marking three consecutive years of growth. The company's latest asset-liability ratio was 28.13%, gross margin was 33.19%, return on equity was 2.13%, and diluted earnings per share was 0.08 yuan.
Lanzhou Foci Pharmaceutical Co LtdNet profit up 32% and operating cash flow up 796.82% in interim report.